Open Label Extension (OLE) of the TDF2 Study, Botswana (TDF2-OLE)
Primary Purpose
HIV Infections
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Sponsored by
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring HIV incidence, HIV prevention, Tenofovir, Emtricitabine, Botswana, HIV seronegativity, PrEP
Eligibility Criteria
Inclusion Criteria:
- Former TDF 2 participants
- Willing and able to provide informed written consent for participation
- If female, willing to use effective contraception during the trial (oral or injectable hormonal contraception, an intrauterine device [IUD], or who have had surgical interventions such as bilateral tubal ligation or hysterectomy)
- Laboratory values as follows within 30 days prior to enrollment:
- HIV uninfected by dual, parallel, rapid whole blood testing and HIV EIA
- Serum phosphorus ≥ 2.2 mg/dL
- Calculated creatinine clearance ≥ 60 mL/min
Exclusion Criteria:
- Positive urine pregnancy test (females)
- Breastfeeding (females)
- History of significant renal or bone disease
- Any other clinical condition or prior therapy that, in the opinion of the physician would make the subject unsuitable for the OLE or unable to comply with the dosing requirements
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
TDF-FTC as PrEP
Arm Description
Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
Outcomes
Primary Outcome Measures
Self-reported Drug Adherence Over the Past 3 Days
A 30-day supply of TDF/FTC was dispensed at each monthly visit, for up to 12 months.
Participants were asked monthly about their drug adherence and were asked to recall their time of dosing over the past 3 days.
Question: "Please think back to [yesterday, 2 days ago, 3 days ago]. What time did you take Truvada? Was it in the morning, afternoon, evening, or you weren't able to take the pill that day?"
Number of Sex Partners
Number of sex partners was assessed at baseline and each scheduled monthly visit, for up to 12 months.
Responses to the following question refers to the number of partners reported in the past 30 days:
"In the past 30 days, with how many partners have you had sexual intercourse?"
Number of Sex Acts by Condom Usage
Number of sex acts by condom usage was assessed at baseline and each scheduled monthly visit, for up to 12 months.
Responses to the following question refers to the number of sex acts with up to 3 partners.
"In the past 30 days, how many times did you have sex with ['this partner']? When I ask about the number of times you had sex, please count each sexual act. For example, if you had 2 rounds of sexual intercourse with your partner on a single evening, count that as two times you had sex. Please remember that this only refers to vaginal and anal sex. It does not refer to oral sex."
To assess condom use by sex act, the following question was asked to assess the number of sex acts with condoms and without condoms with up to 3 partners:
"Of the ___ sex acts, how many times did you not use condoms the entire time?"
Extracellular Tenofovir (TFV) for Recent Drug Exposure
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring extracellular tenofovir (TFV) for recent drug exposure (~24 hours). Of 229 participants, 196 participants had monthly DBSs available for analysis. A sampling algorithm was designed to make inference to TFV and TFV-DP levels at all 12 months. For the TFV extracellular analysis, participants were randomly assigned to one of three sampling schedules, with equal probability: (a) months 1, 2, 5, 8, and 11; (b) months 1, 3, 6, 9, and 12; and (c) months 1, 4, 7, 10, and 12. These 196 participants contributed a total of 777 monthly DBSs for the TFV extracellular analysis.
Extracellular TFV detectability was defined as having a mean TFV level (of up to four measurements) equal to or greater than 5 ng/mL.
Intracellular Tenofovir-diphosphate (TFV-DP)
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring intracellular tenofovir-diphosphate (TFV-DP) for long-term drug exposure (~7 days). The 196 participants who had monthly DBSs available were stratified by site, gender, and the 3 patterns previously assigned for the TFV extracellular analysis (2×2×3 = 12 strata). Then 60 participants were selected, 5 from each of the 12 strata, to balance by site, gender, and the above 3 patterns were maintained. In turn, the monthly DBSs indicated by the assigned pattern were analyzed. These 60 participants contributed a total of 237 monthly DBSs for the TFV-DP intracellular analysis. The observed TFV-DP levels in our study population were categorized as follows (units of drug in fmol/mL): 0 doses per week (<912); 1 dose taken per week (≥912 and <1824); 2 doses taken per week (≥1824 and <2688); 3 doses taken per week (≥2688 and <3600); 4 doses taken per week (≥3600 and <4464); 5 to 7 doses taken
Secondary Outcome Measures
HIV Seroconversion
Study visits were scheduled every month until completion of the study and during monthly study visits, HIV testing was performed, for up to 12 months. During monthly visits, routine HIV testing was performed with two HIV rapid tests. If HIV-infection was suspected, HIV antigen-antibody (Ag/Ab) combination enzyme immunoassay (EIA) (Bio-Rad, GS HIV Combo Ag/Ab EIA) testing was performed, and RNA viral load was measured.
Serious Adverse Events
Study visits were scheduled every month until study completion. Participants were instructed to return to the clinic for evaluation in event of illness. Participants reported any adverse effects (AEs) at monthly or interim visits and were determined as serious adverse events (SAE) when at least possibly related to study drug. DAIDS Table for Grading Severity of Adult Adverse Experiences for Vaccine & Prevention Research Programs was used for grading. Definitions: Grade 3-'probably related'-strong temporal relationship to study product that cannot be explained by participant's clinical state or other factors and a causal relationship is biologically plausible. Grade 4-'definitely related'-distinct temporal relationship to administration of the study product that cannot be explained by the participant's clinical state or other factors or AE occurs on re-challenge or the AE is a known reaction to the product or chemical group or can be predicted by the product's pharmacology.
Full Information
NCT ID
NCT04318210
First Posted
March 3, 2020
Last Updated
May 11, 2022
Sponsor
Centers for Disease Control and Prevention
Collaborators
Botswana Ministry of Health
1. Study Identification
Unique Protocol Identification Number
NCT04318210
Brief Title
Open Label Extension (OLE) of the TDF2 Study, Botswana
Acronym
TDF2-OLE
Official Title
Open Label Extension (OLE) of the Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Completed
Study Start Date
October 2012 (Actual)
Primary Completion Date
July 2014 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centers for Disease Control and Prevention
Collaborators
Botswana Ministry of Health
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is an open label and is an extension to the TDF2 study in which the investigators offered daily oral tenofovir/emtricitabine (TDF/FTC) for a maximum of 12 months to HIV uninfected former participants of the TDF2 study.
Detailed Description
This open label phase builds on a unique opportunity provided by the end of the randomized phase of the TDF 2 study. The randomized study provided a well-characterized cohort of persons who received standard prevention interventions, including monthly testing, counseling, and condoms. The primary intervention that will change in the open label phase is the provision of information about the demonstrated efficacy and safety of PrEP including counseling about how PrEP is not 100% effective, provision of open label rather than blinded study medication, and a shortened visit schedule designed to more closely approximate what would be feasible in an implementation program. This open label phase will therefore serve as an opportunity to gather additional information relevant to the delivery and uptake of daily oral PrEP that may help inform eventual more wide scale PrEP implementation in Botswana.The OLE also leverages unique opportunities to address important questions about how information about PrEP safety and efficacy might affect risk behavior. The randomized trial showed that condom use (81.9% in the TDF/FTC group and 79.7% in the placebo group, p = 0.21) and the number of participants with more than one sexual partner in the previous month (14.2% in the TDF/FTC group and 14.1% in the placebo group, p = 0.86) between the two groups was similar. The underlying premise of this OLE is that information about PrEP efficacy and the knowledge of taking active drug rather than placebo might alter perception of HIV risk. This extension seeks to determine whether this trend will occur in the cohort after individuals receive information and counseling about the partial protective efficacy of PrEP and to identify risk factors for changes in risk behavior. The randomized trial revealed that reported drug adherence between the two arms was almost identical at 84.1% in the TDF/FTC group and 83.7% in the placebo arm (p = 0.79). The investigators have designed this open label phase in order to determine 1) if the knowledge of receiving active drug and the receipt of information about PrEP safety and partial efficacy at the onset of the open label phase could have substantial effects on pill use and 2) to identify individual factors associated with this impact. In addition, the open label extension will provide more information about the long term safety of Truvada.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
HIV incidence, HIV prevention, Tenofovir, Emtricitabine, Botswana, HIV seronegativity, PrEP
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
229 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TDF-FTC as PrEP
Arm Type
Experimental
Arm Description
Eligible HIV-uninfected participants were offered 12 months of oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet regardless of their original study assignment in randomized phase.
Intervention Type
Drug
Intervention Name(s)
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg
Other Intervention Name(s)
Truvada
Primary Outcome Measure Information:
Title
Self-reported Drug Adherence Over the Past 3 Days
Description
A 30-day supply of TDF/FTC was dispensed at each monthly visit, for up to 12 months.
Participants were asked monthly about their drug adherence and were asked to recall their time of dosing over the past 3 days.
Question: "Please think back to [yesterday, 2 days ago, 3 days ago]. What time did you take Truvada? Was it in the morning, afternoon, evening, or you weren't able to take the pill that day?"
Time Frame
Up to 12 Months
Title
Number of Sex Partners
Description
Number of sex partners was assessed at baseline and each scheduled monthly visit, for up to 12 months.
Responses to the following question refers to the number of partners reported in the past 30 days:
"In the past 30 days, with how many partners have you had sexual intercourse?"
Time Frame
Up to 12 months
Title
Number of Sex Acts by Condom Usage
Description
Number of sex acts by condom usage was assessed at baseline and each scheduled monthly visit, for up to 12 months.
Responses to the following question refers to the number of sex acts with up to 3 partners.
"In the past 30 days, how many times did you have sex with ['this partner']? When I ask about the number of times you had sex, please count each sexual act. For example, if you had 2 rounds of sexual intercourse with your partner on a single evening, count that as two times you had sex. Please remember that this only refers to vaginal and anal sex. It does not refer to oral sex."
To assess condom use by sex act, the following question was asked to assess the number of sex acts with condoms and without condoms with up to 3 partners:
"Of the ___ sex acts, how many times did you not use condoms the entire time?"
Time Frame
Up to 12 months
Title
Extracellular Tenofovir (TFV) for Recent Drug Exposure
Description
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring extracellular tenofovir (TFV) for recent drug exposure (~24 hours). Of 229 participants, 196 participants had monthly DBSs available for analysis. A sampling algorithm was designed to make inference to TFV and TFV-DP levels at all 12 months. For the TFV extracellular analysis, participants were randomly assigned to one of three sampling schedules, with equal probability: (a) months 1, 2, 5, 8, and 11; (b) months 1, 3, 6, 9, and 12; and (c) months 1, 4, 7, 10, and 12. These 196 participants contributed a total of 777 monthly DBSs for the TFV extracellular analysis.
Extracellular TFV detectability was defined as having a mean TFV level (of up to four measurements) equal to or greater than 5 ng/mL.
Time Frame
Up to 12 months
Title
Intracellular Tenofovir-diphosphate (TFV-DP)
Description
Dried blood spots were collected at each monthly study visit to characterize drug adherence by measuring intracellular tenofovir-diphosphate (TFV-DP) for long-term drug exposure (~7 days). The 196 participants who had monthly DBSs available were stratified by site, gender, and the 3 patterns previously assigned for the TFV extracellular analysis (2×2×3 = 12 strata). Then 60 participants were selected, 5 from each of the 12 strata, to balance by site, gender, and the above 3 patterns were maintained. In turn, the monthly DBSs indicated by the assigned pattern were analyzed. These 60 participants contributed a total of 237 monthly DBSs for the TFV-DP intracellular analysis. The observed TFV-DP levels in our study population were categorized as follows (units of drug in fmol/mL): 0 doses per week (<912); 1 dose taken per week (≥912 and <1824); 2 doses taken per week (≥1824 and <2688); 3 doses taken per week (≥2688 and <3600); 4 doses taken per week (≥3600 and <4464); 5 to 7 doses taken
Time Frame
Up to 12 months
Secondary Outcome Measure Information:
Title
HIV Seroconversion
Description
Study visits were scheduled every month until completion of the study and during monthly study visits, HIV testing was performed, for up to 12 months. During monthly visits, routine HIV testing was performed with two HIV rapid tests. If HIV-infection was suspected, HIV antigen-antibody (Ag/Ab) combination enzyme immunoassay (EIA) (Bio-Rad, GS HIV Combo Ag/Ab EIA) testing was performed, and RNA viral load was measured.
Time Frame
Up to 12 Months
Title
Serious Adverse Events
Description
Study visits were scheduled every month until study completion. Participants were instructed to return to the clinic for evaluation in event of illness. Participants reported any adverse effects (AEs) at monthly or interim visits and were determined as serious adverse events (SAE) when at least possibly related to study drug. DAIDS Table for Grading Severity of Adult Adverse Experiences for Vaccine & Prevention Research Programs was used for grading. Definitions: Grade 3-'probably related'-strong temporal relationship to study product that cannot be explained by participant's clinical state or other factors and a causal relationship is biologically plausible. Grade 4-'definitely related'-distinct temporal relationship to administration of the study product that cannot be explained by the participant's clinical state or other factors or AE occurs on re-challenge or the AE is a known reaction to the product or chemical group or can be predicted by the product's pharmacology.
Time Frame
Up to 12 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Former TDF 2 participants
Willing and able to provide informed written consent for participation
If female, willing to use effective contraception during the trial (oral or injectable hormonal contraception, an intrauterine device [IUD], or who have had surgical interventions such as bilateral tubal ligation or hysterectomy)
Laboratory values as follows within 30 days prior to enrollment:
HIV uninfected by dual, parallel, rapid whole blood testing and HIV EIA
Serum phosphorus ≥ 2.2 mg/dL
Calculated creatinine clearance ≥ 60 mL/min
Exclusion Criteria:
Positive urine pregnancy test (females)
Breastfeeding (females)
History of significant renal or bone disease
Any other clinical condition or prior therapy that, in the opinion of the physician would make the subject unsuitable for the OLE or unable to comply with the dosing requirements
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Allan Taylor, MD, MPH
Organizational Affiliation
Centers for Disease Control and Prevention
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Data cannot be shared publicly without permission from the country of Botswana but may be available upon request.
Learn more about this trial
Open Label Extension (OLE) of the TDF2 Study, Botswana
We'll reach out to this number within 24 hrs